Christine Shaw is VP at GenMark Diagnostics, Inc. (GNMK). They have made 9 open-market trades across 1 company since 2020, most recently 2021-04-22.
CIK 0001820518
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GNMK | 100,466 | $2.4M |
Shares reported on the most recent Form 4, priced at the 2021-04-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GNMK | SELL | 2021-03-05 | 2021-03-08 | $18.56 | $5K | +19.4% | +19.8% | N/A |
| GNMK | SELL | 2021-02-26 | 2021-03-01 | $17.03 | $107K | -3.3% | +25.2% | N/A |
| GNMK | SELL | 2021-02-23 | 2021-02-25 | $19.21 | $8K | +17.2% | +40.6% | N/A |
| GNMK | SELL | 2021-01-27 | 2021-01-29 | $14.06 | $1K | +22.1% | +37.9% | N/A |
| GNMK | SELL | 2020-12-07 | 2020-12-09 | $13.97 | $4K | +16.1% | +30.0% | +55.7% |
| GNMK | SELL | 2020-11-24 | 2020-11-25 | $13.17 | $5K | +8.8% | +20.2% | +55.1% |
| GNMK | SELL | 2020-10-27 | 2020-10-29 | $11.34 | $771 | -0.4% | +7.9% | +8.3% |
| GNMK | SELL | 2020-09-08 | 2020-09-10 | $11.02 | $3K | +16.6% | +1.6% | +6.9% |
| GNMK | SELL | 2020-08-25 | 2020-08-26 | $14.14 | $5K | -14.2% | +1.7% | -3.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.